secwatch.observer — SEC 8-K summary
======================================

Issuer:     Instil Bio, Inc. (TIL)
CIK:        0001789769
Form:       8-K
Filed at:   2025-03-04T23:59:59+00:00
Accession:  0001789769-25-000012
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Instil Bio Q4 net loss $1.82/sh; cash $115.1M; AXN-2510 NSCLC data expected 1H2025
--------------------------------------------------------------------------------

- GAAP net loss per share $1.82 in Q4, full year $11.39; non-GAAP $1.08 and $7.59 respectively.
- Cash, equivalents, restricted cash and marketable securities $115.1M at Dec 31, 2024, down from $175.0M year-end 2023; runway beyond 2026.
- Clinical data for AXN-2510 (PD-L1xVEGF bispecific) monotherapy in R/R NSCLC anticipated 1H2025; safety data across ~100 patients.
- ImmuneOnco to initiate 1L NSCLC patient enrollment in China Phase 1b/2 trial of AXN-2510 plus chemo in Q2 2025; US trial expected before end of 2025.
- R&D expenses $1.1M Q4 (vs $2.0M prior year); G&A $10.4M Q4; restructuring charges $0.3M Q4.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789769/000178976925000012/0001789769-25-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789769/000178976925000012/til-20250304.htm
  HTML page:      https://secwatch.observer/filing/0001789769-25-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer